enVVeno Medical Corporation NVNO
enVVeno Medical Corporation (Nasdaq: NVNO) is a medical device company. Its next catalyst on record is enVVe System: Commence first stage of TAVVE pivotal study (10 patients) (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: enVVe System — Commence first stage of TAVVE pivotal study (10 patients) (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| enVVe System (TAVVE pivotal study) | Severe deep venous Chronic Venous Insufficiency | device-combination | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.